Summary:
Prospective, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil 600 mg PO, BID for 5 Days Versus Placebo Versus Telithromycin In the Treatment of Acute Exacerbation of Chronic Bronchitis
Qualified Participants Must:
• Must be male or non-pregnant female age greater than 35yrs with significant COPD, chronic cough and sputum production and acute exacerbation of chronic bronchitis
•Must have past or current history of smoking(over 10 pack years) and/or evidence of airflow obstruction
•must be able to provide a purulent or muco-purulrnt sputum by deep expectoration for culture and suceptibility testing on the day of study enrollment
Qualified Participants May Receive:
Appropriately for time and travel